Physician profile
Chan Chen
NPI 1619322575
$899.08
in general payments reported to CMS, 2019-2025
10 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $135 · 2023: $16.97 · 2024: $128 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $264.09 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Dexcom, INC. | $124.25 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Astrazeneca Pharmaceuticals LP | $122.75 | 2022 | |
| Novo Nordisk INC | $118.04 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $110.16 | 2025 | Zeposia |
| Celgene Corporation | $69.21 | 2023-2025 | Zeposia |
| Ucb, INC. | $42.10 | 2024-2025 | Briviact |
| Bayer Healthcare Pharmaceuticals INC. | $19.85 | 2024 | |
| Genentech USA, INC. | $16.18 | 2025 | Ocrevus Zunovo |
| Melinta Therapeutics, LLC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.